Lupin signed a licensing and supply deal with SteinCares for its eye disease drug biosimilar Ranibizumab in Latin America.
The deets: Lupin is a global Indian pharma player known for generics, biosimilars, and specialty drugs. SteinCares is a Latin American healthcare company focused on biosimilars and affordable medicines.
- Ranibizumab is a biosimilar used to treat vision-threatening retinal disorders like age-related macular degeneration and diabetic macular edema.
Under the deal, Lupin will handle manufacturing, while SteinCares will lead regulatory filings and commercialisation.
Why it matters: retinal diseases like macular degeneration and diabetic macular edema are major causes of vision loss. A cost-effective biosimilar can boost treatment access and affordability, especially in Latin America, where need is high and options are limited.
